RayKnowChina Research Map
Shortlist

RecruitingLung cancerBreast cancerPhase 1

Registered title, quoted from ClinicalTrials.gov

VSV-02 Compassionate Use in Advanced Solid Tumors

An open trial on lung cancer and breast cancer, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Xinxiang Medical University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFirst Affiliated Hospital of Xinxiang Medical University河南医药大学第一附属医院XinxiangHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07260591, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 1

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (1 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07260591, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

Voluntary signed informed consent.

Age ≥ 18 years.

Histologically or cytologically confirmed advanced solid tumor (e.g., melanoma, head and neck squamous cell carcinoma, cervical cancer, osteosarcoma, nasopharyngeal carcinoma, breast cancer, lung cancer, colorectal cancer, liver cancer, gastric cancer).

Disease progression after at least two prior lines of standard therapy (including targeted therapy), or for whom no standard therapy exists or is medically unsuitable.

At least one measurable lesion per RECIST 1.1 criteria.

At least one lesion accessible for intratumoral injection.

ECOG performance status of 0-2.

Life expectancy ≥ 12 weeks.

Adequate organ and bone marrow function.

Negative pregnancy test for women of childbearing potential.

Agreement to use effective contraception during the study and for at least 6 months after the last dose.

Exclusion Criteria:

Symptomatic or untreated brain metastases (asymptomatic or stable for ≥3 months after local therapy allowed).

Radiotherapy to the target lesion within 2 months.

History of other active malignancy within 5 years (with specific exceptions).

Lesion intended for injection with a longest diameter > 100 mm.

Participation in another interventional clinical trial within 4 weeks.

Prior or planned organ/tissue transplantation.

Active HIV, Hepatitis B, Hepatitis C, or Syphilis infection meeting specific criteria.

Requirement for concomitant antiviral or therapeutic anticoagulation.

Uncontrolled ≥ Grade 3 active infection.

Specific washout periods for prior anti-cancer therapies not met.

Uncontrolled cardiovascular disease.

Active or history of autoimmune disease (with specific exceptions).

Requirement for systemic corticosteroids (>10 mg prednisone equivalent) within 14 days or during the study.

Tumors located in high-risk anatomical sites.

Administration of live vaccines during the study period.

Known hypersensitivity to any component of the study drug or related immunotherapies.

History of severe mental illness, substance abuse, or other conditions that may interfere with study compliance.

Pregnancy or lactation.

Toxicities from previous anti-cancer therapy not recovered to ≤ Grade 1 (except alopecia).

Any other condition deemed inappropriate for participation by the investigator.

Quoted from ClinicalTrials.gov, NCT07260591, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07260591, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07260591